AnaptysBio (NASDAQ:ANAB) Downgraded by StockNews.com

AnaptysBio (NASDAQ:ANAB – Get Rating) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities analysts have also recently issued reports about the stock. Wedbush upped their price target on shares of AnaptysBio from $21.00 to $32.00 in a research report on Wednesday, November 9th. Raymond James cut shares of AnaptysBio from an “outperform” rating to a “market perform” rating in a research report on Friday, January 6th. Guggenheim upgraded shares of AnaptysBio from a “neutral” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Tuesday, November 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of AnaptysBio from $24.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, November 18th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, AnaptysBio presently has a consensus rating of “Hold” and a consensus price target of $34.83.

AnaptysBio Price Performance

ANAB stock opened at $25.00 on Friday. AnaptysBio has a 1 year low of $18.20 and a 1 year high of $34.33. The company has a 50 day simple moving average of $27.63 and a 200 day simple moving average of $25.87. The stock has a market cap of $710.80 million, a price-to-earnings ratio of -5.19 and a beta of -0.08.

AnaptysBio (NASDAQ:ANAB – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($1.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.71). AnaptysBio had a negative net margin of 3,003.32% and a negative return on equity of 42.04%. The business had revenue of $1.29 million during the quarter, compared to analyst estimates of $17.36 million. On average, equities research analysts anticipate that AnaptysBio will post -4.07 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in AnaptysBio during the second quarter worth $34,000. US Bancorp DE lifted its stake in shares of AnaptysBio by 44.4% in the third quarter. US Bancorp DE now owns 1,538 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 473 shares in the last quarter. Amalgamated Bank bought a new position in shares of AnaptysBio in the first quarter valued at $57,000. BNP Paribas Arbitrage SA lifted its stake in shares of AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 2,142 shares in the last quarter. Finally, The Manufacturers Life Insurance Company bought a new position in shares of AnaptysBio in the third quarter valued at $211,000.

AnaptysBio Company Profile

(Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.